Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2018 1
2019 2
2020 4
2021 6
2022 6
2023 4
2024 7
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study.
Robert M, Poghosyan T, Maucort-Boulch D, Filippello A, Caiazzo R, Sterkers A, Khamphommala L, Reche F, Malherbe V, Torcivia A, Saber T, Delaunay D, Langlois-Jacques C, Suffisseau A, Bin S, Disse E, Pattou F. Robert M, et al. Among authors: langlois jacques c. Lancet Diabetes Endocrinol. 2024 Apr;12(4):267-276. doi: 10.1016/S2213-8587(24)00035-4. Epub 2024 Mar 4. Lancet Diabetes Endocrinol. 2024. PMID: 38452784 Clinical Trial.
Efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy versus Roux-en-Y gastric bypass in France (SADISLEEVE): results of a randomised, open-label, superiority trial at 2 years of follow-up.
Robert M, Poghosyan T, Romain-Scelle N, Czernichow S, Delaunay D, Sterkers A, Khamphommala L, Lazzati A, Blanchard C, Caiazzo R, Pattou F, Disse E; SADISLEEVE Collaborative Group. Robert M, et al. Lancet. 2025 Aug 23;406(10505):846-859. doi: 10.1016/S0140-6736(25)01070-0. Lancet. 2025. PMID: 40849141 Clinical Trial.
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia.
Msika A, Mathias V, Boudigou M, Chambon M, Dubois V, Hajri T, Lotz JP, Massardier J, Descargues P, Gladieff L, Joly F, Lebreton C, Maucort-Boulch D, Bin S, Rousset P, Allias F, Gaillot-Durand L, Devouassoux-Shisheboran M, Lemaitre N, Alfaidy N, Langlois-Jacques C, Alves-Ferreira M, Golfier F, You B, Thaunat O, Bolze PA, Koenig A. Msika A, et al. Among authors: langlois jacques c. Am J Obstet Gynecol. 2025 Apr;232(4):381.e1-381.e11. doi: 10.1016/j.ajog.2024.09.115. Epub 2024 Oct 5. Am J Obstet Gynecol. 2025. PMID: 39370035 Free article.
Deep brain stimulation for severe dystonia associated with Wilson disease: A prospective multicenter meta-analysis of an N-of-1 trial.
Laurencin C, Poujois A, Bonjour M, Demily C, Klinger H, Roze E, Leclert V, Danaila T, Langlois-Jacques C, Couchonnal E, Woimant F, Obadia MA, Perez G, Pernon M, Blanchet L, Broussolle E, Vidailhet M, Kassai B, Moro E, Karachi C, Polo G, Grabli D, Portefaix A, Thobois S. Laurencin C, et al. Among authors: langlois jacques c. Eur J Neurol. 2025 Jan;32(1):e16524. doi: 10.1111/ene.16524. Epub 2024 Oct 29. Eur J Neurol. 2025. PMID: 39468897 Free PMC article.
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Freyer G, et al. Among authors: langlois jacques c. Nat Commun. 2024 Mar 5;15(1):1985. doi: 10.1038/s41467-024-45974-w. Nat Commun. 2024. PMID: 38443333 Free PMC article. Clinical Trial.
Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study.
You B, Couraud S, Ceruse P, Badet L, Paparel P, Durand A, Guillet M, Merle P, Lescuyer G, Philip CA, Ducray F, Pioche M, Karlin L, Lifante JC, Glehen O, Bolze PA, Chauvenet M, Langlois-Jacques C, Subtil F, Piecyk M, Carrot A, Joubert D, Prieur A, Vire B, Calattini S, Payen L. You B, et al. Among authors: langlois jacques c. Biomark Res. 2025 Jul 1;13(1):91. doi: 10.1186/s40364-025-00793-z. Biomark Res. 2025. PMID: 40598473 Free PMC article.
Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects.
Saker K, Pozzetto B, Escuret V, Pitiot V, Massardier-Pilonchéry A, Mokdad B, Langlois-Jacques C, Rabilloud M, Alfaiate D, Guibert N, Fassier JB, Bal A, Trouillet-Assant S, Trabaud MA. Saker K, et al. Among authors: langlois jacques c. J Clin Virol. 2022 Jul;152:105169. doi: 10.1016/j.jcv.2022.105169. Epub 2022 Apr 27. J Clin Virol. 2022. PMID: 35568003 Free PMC article.
Effectiveness of integrated vector management on the incidence of dengue in urban Malaysia: a cluster-randomised controlled trial.
Saadatian-Elahi M, Rabilloud M, Möhlmann TWR, Langlois-Jacques C, Ariffin FD, Farenhorst M, Elsensohn MH, Schmitt F, Richardson JH, Baur F, Leduc M, Romli NN, Tan LK, Norazman MR, Shahar H, Mudin RN, Alexander N, Ab Hamid N. Saadatian-Elahi M, et al. Among authors: langlois jacques c. Lancet Infect Dis. 2025 Sep;25(9):977-985. doi: 10.1016/S1473-3099(25)00086-6. Epub 2025 May 12. Lancet Infect Dis. 2025. PMID: 40373783 Clinical Trial.
30 results